ORTEXORTEX News
Tracking BR? Get live short interest, options flow, and signals on ORTEX.Sign up free →
BR
Earnings PreviewBR

Broadridge Shorts Ease as Stock Outpaces Peers Before Results

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 4 Nov 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Broadridge Financial Solutions reports first-quarter results today with its stock up 3.8% over the past week, outpacing a median decline of roughly 0.5% among its closest peers.

Short sellers have trimmed their exposure modestly into the print. Shares short fell 0.5% on November 2 to around 3.05 million, leaving short interest at 2.6% of the free float. That is a low level by any measure, and borrow availability is effectively unconstrained, with more than 111 million shares available to lend against roughly 3 million already borrowed. Borrowing costs remain cheap at 0.64%, though that figure has roughly tripled since early October, rising from around 0.21% on October 2. The cost is still well below any threshold that would impede a short position, so the move is more of a footnote than a signal.

Options positioning has grown more defensive since the previous preview noted the shift. The put/call ratio reached 0.46 on November 3, running about one standard deviation above its 20-day average of 0.38. That is softer than the 1.7 standard deviation gap flagged four days ago, as the ratio has pulled back slightly from the 0.50 area seen in late October. The pattern through the data is clear: the ratio spent most of October below 0.30 before moving decisively higher in the final two weeks, reflecting demand for downside protection that was not present earlier in the month.

Analyst opinion is broadly constructive, though targets sit well above the current price. RBC Capital holds an Outperform rating with a $226 target, raised last August after the previous quarterly print, when the stock rose 1% on the day and 5.5% over the following five sessions. Morgan Stanley's Equal-Weight rating carries a $176 target, the only major-firm note below the current price of $183.76. DA Davidson reiterated its Buy and $214 target on October 27. The debate centres on recurring revenue momentum, which bulls point to at 9.2% year-on-year growth, against the sharp decline in event-driven revenue, down 27% in the most recent quarter, which bears cite as a constraint on near-term upside. Adjusted operating margins are expected to stay flat at 20 to 21%, leaving little room for a valuation re-rating unless closed sales growth accelerates from the 24% pace reported last quarter.

Today's print will test whether recurring revenue growth has held its pace and whether event-driven weakness has stabilised, two questions whose answers will determine whether the stock's 17% one-month rally is supported by the fundamentals beneath it.

Stocks in this article

See the live data behind this article on ORTEX.

Open BR on ORTEX →

How this article was generated

Generated
4 Nov 2026, 04:11
Data as of
4 Nov 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.